Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies ...

In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...

,A weight-loss drug more effective than Ozempic and Wegovy has recently been approved in Australia. The drug, tirzepatide, is ...

Eli Lilly (NYSE: LLY) sells treatments for a wide variety of therapeutic areas, but one portfolio in particular has driven ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Compounding pharmacies can make tirzepatide againIn a reversal, the Food and Drug Administration ...

On October 7, a compounding trade group filed a lawsuit challenging the agency's action, saying there was still a shortage of the wildly popular drug.

Pharmacists can continue making compounded versions of generic tirzepatide, the active ingredient in popular medications ...

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

A group of health professionals have called for a review of obesity management services in light of increased public demand ...

Streeting announced a collaboration with the world's largest pharmaceutical company, Lilly, which will include a five-year ...